ETON vs. IMCR, GLPG, AGIO, TWST, IDYA, TARS, CNTA, RXRX, INDV, and APGE
Should you be buying Eton Pharmaceuticals stock or one of its competitors? The main competitors of Eton Pharmaceuticals include Immunocore (IMCR), Galapagos (GLPG), Agios Pharmaceuticals (AGIO), Twist Bioscience (TWST), IDEAYA Biosciences (IDYA), Tarsus Pharmaceuticals (TARS), Centessa Pharmaceuticals (CNTA), Recursion Pharmaceuticals (RXRX), Indivior (INDV), and Apogee Therapeutics (APGE). These companies are all part of the "pharmaceutical products" industry.
Eton Pharmaceuticals vs. Its Competitors
Eton Pharmaceuticals (NASDAQ:ETON) and Immunocore (NASDAQ:IMCR) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, dividends, valuation, earnings, profitability, community ranking, risk, institutional ownership and media sentiment.
Eton Pharmaceuticals has a beta of 1.28, meaning that its stock price is 28% more volatile than the S&P 500. Comparatively, Immunocore has a beta of 0.83, meaning that its stock price is 17% less volatile than the S&P 500.
In the previous week, Eton Pharmaceuticals had 3 more articles in the media than Immunocore. MarketBeat recorded 14 mentions for Eton Pharmaceuticals and 11 mentions for Immunocore. Immunocore's average media sentiment score of 0.97 beat Eton Pharmaceuticals' score of 0.97 indicating that Immunocore is being referred to more favorably in the news media.
Eton Pharmaceuticals received 26 more outperform votes than Immunocore when rated by MarketBeat users. However, 73.53% of users gave Immunocore an outperform vote while only 66.45% of users gave Eton Pharmaceuticals an outperform vote.
Eton Pharmaceuticals presently has a consensus target price of $29.67, suggesting a potential upside of 96.60%. Immunocore has a consensus target price of $58.89, suggesting a potential upside of 65.60%. Given Eton Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Eton Pharmaceuticals is more favorable than Immunocore.
Eton Pharmaceuticals has higher earnings, but lower revenue than Immunocore. Eton Pharmaceuticals is trading at a lower price-to-earnings ratio than Immunocore, indicating that it is currently the more affordable of the two stocks.
Eton Pharmaceuticals has a net margin of -15.81% compared to Immunocore's net margin of -15.87%. Immunocore's return on equity of -12.84% beat Eton Pharmaceuticals' return on equity.
27.9% of Eton Pharmaceuticals shares are held by institutional investors. Comparatively, 84.5% of Immunocore shares are held by institutional investors. 16.0% of Eton Pharmaceuticals shares are held by insiders. Comparatively, 10.4% of Immunocore shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Summary
Eton Pharmaceuticals beats Immunocore on 10 of the 18 factors compared between the two stocks.
Get Eton Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ETON and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ETON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Eton Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:ETON) was last updated on 6/12/2025 by MarketBeat.com Staff
Buy ETON Stock Free ETON Stock Alerts